Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Cancer & Oncology — Weekly Report — September 28, 2026

Home/Health Insights/Cancer & Oncology — September 28 – October 5, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Cancer & Oncology
Updated Monday · November 16, 2026
Cancer & Oncology · September 28 – October 5, 2026

Cancer & Oncology
Weekly Report

This week's data 167 new clinical trials registered across 10 countries, with 18,761 trials actively recruiting patients worldwide.
Week of September 28 – October 5, 2026
  • 167 new clinical trials registered across 10 countries.
  • 18,761 trials actively recruiting patients worldwide.
  • Notable trial: Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (2300 patients).
  • 8,782 new research papers published.
  • Drug safety: Most reported effect across tracked medications (pembrolizumab, nivolumab, trastuzumab, rituximab, paclitaxel) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · September 28 – October 5, 2026
New Trials This Week
167.
registered Sep 28–Oct 5
Recruiting Now
18,761
active trials seeking patients
Countries
10
with active trials this week
Papers Published
8,782
new studies this week
Phase 3 Trials
2
late-stage trials this week
Fig. 01

Trials by country

Count · September 28 – October 5, 2026
China
28
United States
28
South Korea
20
France
19
Not specified
14
Italy
3
Turkey (Türkiye)
3
Spain
2
United Kingdom
1
Switzerland
1
0 7 14 21 28
total
Fig. 02

Trials by phase

Distribution · September 28 – October 5, 2026

New clinical trials registered this week for Cancer & Oncology. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

167 trials registered for Cancer & Oncology. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 To Evaluate the Safety and Efficacy of RNK08954 in Patients With Advanced Gynecological Tumors. Cancer & Oncology · Ranok Therapuetics Co. Ltd. (NCT07848893) Phase 2 Not Yet Recruiting 120 China
02 Lidocaine Infusions for Pain in Patients With Malignant Bowel Obstruction Cancer & Oncology · Fundación Santa Fe de Bogota (NCT07856251) Other Not Yet Recruiting 50 N/A
03 A Study of Music Therapy for Anxiety in People With Cancer Cancer & Oncology · Memorial Sloan Kettering Cancer Center (NCT07845422) Other Recruiting 240 United States
04 Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder Cancer & Oncology · OHSU Knight Cancer Institute (NCT07844694) Phase 1 Recruiting 6 United States
05 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features Cancer & Oncology · Shengjing Hospital (NCT07844460) Other Enrolling By Invitation 30 China
06 A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment Cancer & Oncology · Incyte Corporation (NCT07853040) Phase 1 Not Yet Recruiting 24 N/A
07 REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants Cancer & Oncology · Regeneron Pharmaceuticals (NCT07850921) Phase 2 Not Yet Recruiting 192 N/A
08 Metabolic and Hormonal Parameters in Women With Polyendocrine Metabolic Ovarian Syndrome Cancer & Oncology · Istinye University (NCT07844785) Other Not Yet Recruiting 80 N/A
09 TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread Cancer & Oncology · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (NCT07844187) Phase 2 Not Yet Recruiting 64 China
10 VAAPS Combined With Loose Seton Drainage for Postoperative Self-Care: A Prospective Single-Arm Cohort Study Cancer & Oncology · Peking University People's Hospital (NCT07855107) Other Recruiting 50 China
11 GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma Cancer & Oncology · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (NCT07852975) Other Not Yet Recruiting 20 United States
12 Long-Term Patient Reported Outcomes Following Surgery for Spinal Intradural Tumours Cancer & Oncology · Walton Centre NHS Foundation Trust (NCT07849868) Other Completed 150 United Kingdom
13 A First-in-Human Study of ¹⁷⁷Lu-HX02 in Sarcoma Patients Cancer & Oncology · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (NCT07847268) Other Completed 9 China
14 An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With 177Lu-PSMA-617 vs Androgen Receptor Pathway Inhibitor (ARPI) Switch in Routine Care Cancer & Oncology · Novartis Pharmaceuticals (NCT07843758) Other Completed 1,525 Switzerland
15 Improving Goals of Care Conversations Between Doctors and Young Adults With Cancer Cancer & Oncology · Memorial Sloan Kettering Cancer Center (NCT07855484) Other Recruiting 118 United States
16 A Master Regulator of Lipid-Associated Macrophage Function in Cancer Cancer & Oncology · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (NCT07848061) Other Not Yet Recruiting 120 Italy
17 A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal Cancer Cancer & Oncology · Tang-Du Hospital (NCT07854964) Other Not Yet Recruiting 37 N/A
18 Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise) Cancer & Oncology · Technical University of Munich (NCT07851493) Other Recruiting 80 Germany
19 BRCC36 and Telomerase Levels in Women With Polycystic Ovary Syndrome Cancer & Oncology · Cumhuriyet University (NCT07849166) Other Completed 60 Turkey (Türkiye)
20 Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes Cancer & Oncology · Peking University Cancer Hospital & Institute (NCT07848243) Phase 2 Recruiting 50 China
21 Hemodynamic Effects of Trendelenburg Position and Pneumoperitoneum in Urologic Robotic Surgery Cancer & Oncology · Ege University (NCT07848581) Other Completed 55 Turkey (Türkiye)
22 Application of Precision Partial Intersphincteric Resection (PPISR) Cancer & Oncology · First Affiliated Hospital of Wenzhou Medical University (NCT07849023) Other Recruiting 100 China
23 Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer. Cancer & Oncology · Centre Antoine Lacassagne (NCT07847398) Other Not Yet Recruiting 50 France
24 Safety and Effectiveness of Robotic-Assisted Remote Surgery for Breast Tumors Cancer & Oncology · Guangzhou Women and Children's Medical Center (NCT07850323) Other Completed 25 China
25 The LifeMeds Cohort Cancer & Oncology · Tilburg University (NCT07846800) Other Not Yet Recruiting 2,000 N/A
26 Screening Psychosocial Distress in Head and Neck Cancer Cancer & Oncology · Hôpital NOVO (NCT07851818) Other Not Yet Recruiting 80 N/A
27 Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Cancer & Oncology · Dana-Farber Cancer Institute (NCT07847957) Phase 2 Not Yet Recruiting 40 United States
28 Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer Cancer & Oncology · King Faisal Specialist Hospital & Research Center (NCT07844473) Other Recruiting 35 Saudi Arabia
29 miRNA to Guide Appropriate Intervention of Small Testis Masses Cancer & Oncology · University Health Network, Toronto (NCT07852871) Other Recruiting 100 Canada
30 Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study Cancer & Oncology · Thomas Jefferson University (NCT07849543) Other Not Yet Recruiting 190 N/A
31 Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma Cancer & Oncology · All India Institute of Medical Sciences (NCT07845097) Phase 2 Not Yet Recruiting 90 N/A
32 Artificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast Cancer Cancer & Oncology · Shanghai Jiao Tong University School of Medicine (NCT07844941) Other Recruiting 60 China
33 InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma Cancer & Oncology · Beijing Municipal Administration of Hospitals (NCT07848750) Other Recruiting 40 China
34 A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer Cancer & Oncology · Boehringer Ingelheim (NCT07851103) Phase 1 Not Yet Recruiting 90 United States
35 A Study of RT036 in Patients With Advanced Solid Tumors Cancer & Oncology · Shanghai Ruotuo Biosciences Co., Ltd. (NCT07844447) Phase 2 Not Yet Recruiting 308 N/A
36 The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With Lung Cancer Cancer & Oncology · Izmir Bakircay University (NCT07847138) Other Completed 50 Turkey (Türkiye)
37 A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 Cancer & Oncology · Jiangsu Hansoh Pharmaceutical Co., Ltd. (NCT07844967) Phase 1 Recruiting 32 China
38 Lenvatinib in Patients With Advanced Parathyroid Carcinoma Cancer & Oncology · Yonsei University (NCT07843901) Phase 2 Not Yet Recruiting 18 N/A
39 Supporting Families In Coping With Parental Cancer: A Multi-Site Randomized Controlled Trial Cancer & Oncology · M.D. Anderson Cancer Center (NCT07852858) Other Not Yet Recruiting 400 United States
40 A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer Cancer & Oncology · FutureChem (NCT07853209) Phase 3 Recruiting 114 South Korea
41 Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Cancer & Oncology · Exelixis (NCT07845786) Phase 2 Not Yet Recruiting 60 N/A
42 Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision Cancer & Oncology · University of Minnesota (NCT07844681) Other Not Yet Recruiting 300 United States
43 Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment Cancer & Oncology · Bojan Kovacevic (NCT07850336) Other Not Yet Recruiting 56 N/A
44 Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism Cancer & Oncology · Samsung Medical Center (NCT07852637) Phase 4 Not Yet Recruiting 2,300 South Korea
45 SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years Cancer & Oncology · University Hospital, Angers (NCT07845994) Phase 3 Not Yet Recruiting 50 France
46 Epstein-Barr Virus Antibodies in Egyptian Patients With Multiple Sclerosis Cancer & Oncology · Assiut University (NCT07846943) Other Not Yet Recruiting 140 N/A
47 PROPOSAL FOR A PREOPERATIVE FUNCTIONAL OPTIMIZATION PATHWAY FOR PATIENTS CANDIDATE FOR MAJOR SURGERY (CARDIAC AND ABDOMINAL ONCOLOGY) Cancer & Oncology · ASST Sette Laghi (NCT07851350) Other Recruiting 50 Italy
48 SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response Cancer & Oncology · Fudan University (NCT07856303) Phase 2 Not Yet Recruiting 358 China
49 The Precision Mito- Mito Map COMPASS Study Cancer & Oncology · AI Agent Vault, Inc. d/b/a Precision Mito (NCT07856121) Other Not Yet Recruiting 400 United States
50 A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer Cancer & Oncology · Haitao Zhao, MD (NCT07854600) Phase 2 Recruiting 87 China
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Cancer & Oncology. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
pembrolizumab Malignant Neoplasm Progression 1,762
nivolumab Off Label Use 819
trastuzumab Myelosuppression 717
rituximab Off Label Use 5,555
paclitaxel Myelosuppression 1,062

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Cancer & Oncology. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

8,782 papers

Recently published peer-reviewed studies related to Cancer & Oncology, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group. Calabrò C et al. 10.1080/17512433.2026.2744573
View abstract

INTRODUCTION: In recent years, studies have demonstrated that in urothelial carcinoma (UC), the rate of HER-2 protein overexpression (immunohistochemistry 2+ and 3+) ranges from 18.1% to 36%, and the rate of HER-2 gene amplification reaches 10%-23%. The advent of HER-2-targeted antibody-drug conjugates and immune checkpoint inhibitors has reshaped the treatment landscape of advanced urothelial carcinoma. AREAS COVERED: In the current paper, we discuss the role of disitamab vedotin as an innovative anticancer therapy in UC patients, with a specific focus on available evidence and ongoing clinical trials. A literature search of PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov (through May 2026) was performed using the terms 'disitamab vedotin,' 'RC48-ADC,' and 'urothelial carcinoma.' EXPERT OPINION: As ADC-based strategies continue to expand in UC, further studies will be needed to better understand how DV should be integrated with other anticancer approaches in this setting, particularly in terms of patient selection and treatment sequencing.

Expert review of clinical pharmacology 2026 Oct 4 PubMed
02 Bacterial Nanocellulose as a Platform for Three-Dimensional Colon Cancer Cultures: Physicochemical Characterization and Biocompatibility Evaluation. Londoño M et al. 10.1002/mabi.70272
View abstract

3D in vitro cancer models provide a more physiologically relevant representation of tumor architecture and cell-matrix interactions than conventional monolayer cultures. This study evaluated bacterial nanocellulose (BNC) as a scaffold for the 3D culture of colorectal cancer cells. BNC scaffolds were produced using paraffin spheres as porogens and subsequently characterized in terms of morphology, chemical structure, thermal stability, and mechanical properties. Human colorectal cancer cell lines SW480 and SW620, along with CHO-K1 cells, were exposed to BNC leachates and cultured on 2D and 3D BNC matrices. Cells grown on 2D BNC exhibited typical monolayer proliferation, whereas 3D matrices allowed cell infiltration and volumetric distribution, supporting multicellular organization and the formation of spheroid-like aggregates. Cell viability remained in both leachate and direct scaffold cultures. Genotoxicity assays showed low levels of DNA damage, with most cells displaying no detectable genotoxic effects, and mutagenicity tests revealed no significant differences compared to controls (p > 0.05). Overall, the results demonstrate that 3D BNC supports cell viability, multicellular organization, and genomic safety, highlighting its suitability as a biocompatible scaffold for in vitro 3D colon cancer models.

Macromolecular bioscience 2026 Oct PubMed
03 Development and Validation of a Predictive Model for Subclinical Myocardial Dysfunction in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy: Integrating 2D Speckle Tracking Echocardiography and Conventional Echocardiographic Parameters. Wang S et al. 10.1111/echo.70637
View abstract

BACKGROUND: Anthracycline cardiotoxicity is often silent at the subclinical stage. Left ventricular ejection fraction (LVEF) detects injury late, and global longitudinal strain (GLS) is sensitive but usually used alone. This study aimed to develop and internally validate a baseline model combining speckle-tracking GLS, conventional echocardiography, and clinical factors to identify women at high risk of subclinical myocardial dysfunction before doxorubicin (DOX) chemotherapy. METHODS: In a single-center prospective study, 200 breast cancer patients scheduled for DOX-based chemotherapy underwent baseline and 1-month assessment. The primary outcome was subclinical myocardial dysfunction, defined as > 15% relative GLS reduction with preserved LVEF. P < 0.10 variables in univariable analysis entered multivariable logistic regression for nomogram construction. Discrimination, calibration, and decision curve analysis used 1000-bootstrap validation. RESULTS: Subclinical myocardial dysfunction occurred in 60 of 200 patients (30.0%). Independent predictors were baseline GLS, LDL-C, trastuzumab use, planned cumulative dose, LAVI, and hypertension. The model reached an AUC of 0.803, higher than baseline GLS, a clinical-only model, and baseline LVEF. The bootstrap-corrected C-index was 0.777. CONCLUSION: A baseline nomogram combining GLS, conventional echocardiography, and clinical factors may help identify patients at high risk of early subclinical myocardial dysfunction before chemotherapy, outperforming single parameters and supporting risk-stratified monitoring.

Echocardiography (Mount Kisco, N.Y.) 2026 Oct PubMed
04 Pulmonary Alveolar Proteinosis After Allogeneic Stem Cell Transplant in a Patient Undergoing Multiagent Chronic Graft-Versus-Host-Disease Treatment Including Axatilimab. Nichols C et al. 10.1002/ajh.70517 American journal of hematology 2026 Oct 4 PubMed
05 Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance - a review. Zhou L et al. 10.1080/1120009X.2026.2739728
View abstract

Malignant tumors remain a leading cause of global mortality, and the development of chemoresistance represents a major obstacle to effective cancer treatment. Long non-coding RNAs (lncRNAs) are important regulators of tumor progression and therapeutic response. Cancer susceptibility candidate 2 (CASC2) is an lncRNA that is generally downregulated in malignant tumors and has been implicated in the regulation of chemoresistance. CASC2 influences therapeutic responsiveness through multiple mechanisms, including modulation of apoptosis and oncogenic signaling pathways, competitive binding to specific miRNAs, regulation of protein stability and RNA-protein interactions, and epigenetic gene regulation. Notably, its effects may vary according to tumor type and treatment context. This review systematically summarizes the regulatory roles and molecular mechanisms of CASC2 in tumor chemoresistance and discusses its potential clinical and therapeutic implications.

Journal of chemotherapy (Florence, Italy) 2026 Oct 4 PubMed
06 Orthogonal Light- and Enzyme-Triggered and-Gate Prodrugs for Senolytic Therapy. Chang M et al. 10.1002/advs.78139
View abstract

Senescence-associated β-galactosidase (SA-β-gal) is widely used to target senescent cells, but its activity in non-senescent tissues can limit selectivity. Here, we developed a light-enzyme AND-gate strategy in which an o-nitrobenzyl photocage blocks β-galactoside cleavage until 390 nm irradiation. The strategy was evaluated using a fluorescent probe (LS-C), a doxorubicin prodrug (LS-D), and an ARV-771-based PROTAC (LS-A). LS-C exhibited dual-trigger-dependent fluorescence activation, while LS-D preferentially induced apoptosis and LS-A promoted BRD4 degradation in senescent cells following light activation. Across multiple senescence models, LS-D and LS-A showed higher senolytic indices than their corresponding parent compounds. In senescent lung cancer patient-derived organoids, LS-D combined with light increased organoid death, whereas either treatment alone had minimal effects. These results provide proof-of-concept evidence for sequential light-enzyme AND-gating as a strategy for controlling payload activation in senescent cells under the tested in vitro and ex vivo conditions.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Oct 4 PubMed
07 Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia. Daver NG et al. 10.1002/cncr.70626
View abstract

BACKGROUND: This clinical trial sought to determine whether SL-172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher-risk myelodysplastic syndrome (HR-MDS) or acute myeloid leukemia (AML). METHODS: Dose escalation: doses of 1, 3, and 6 mg/kg SL-172154 was evaluated as monotherapy or in combination with AZA in patients with relapsed, refractory HR-MDS or AML. Expansion: a SL-172154 dose that could be safely combined with AZA was evaluated in patients with previously untreated HR-MDS or TP53 mutant (TP53m) AML. OBJECTIVES: safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity. RESULTS: Eighty-one patients with HR-MDS (n = 33) or AML (n = 48) were enrolled in dose escalation (n = 37) or expansion (n = 44). Infusion-related reaction was the most common SL-172154-related toxicity and led to a dose limiting toxicity at 6 mg/kg. A dose of 3 mg/kg SL-172154 plus AZA was evaluated in patients with previously untreated HR-MDS (n = 21 with TP53m and n = 3 with TP53 wild type) and AML (n = 21 with TP53m). CD47 and CD40 engagement by SL-172154 was detected on leukemic blasts, myeloid, and lymphoid cells. Complete remission (CR) was achieved in 10 of 24 (43%) HR-MDS and six of 21 (29%) TP53m AML patients with median overall survival (OS) of 11.0 months (95% CI, 5.0-15.6) and 11.7 months (95% CI, 1.97-NE), respectively. Of patients in a CR, six of 10 HR-MDS and three of six TP53m AML patients achieved complete cytogenetic CR. CONCLUSIONS: SL-172154 plus AZA was generally well tolerated with favorable CR rates in pts with TP53m HR-MDS or AML, although without substantial improvement in OS when compared to historical benchmarks for AZA or AZA/VEN, respectively.

Cancer 2026 Oct 1 PubMed
08 N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial. Tahmasebi M et al. 10.1007/s00520-026-11286-6
View abstract

PURPOSE: Oral mucositis (OM) is a frequent and clinically important toxicity of conditioning therapy for hematopoietic cell transplantation (HCT). This trial evaluated whether prophylactic N-acetylcysteine (NAC) mouthwash reduces the incidence and severity of OM in HCT recipients. METHODS: In this single-center, double-blind, randomized, placebo-controlled trial, adults undergoing autologous or allogeneic HCT were assigned 1:1 to NAC mouthwash (600 mg every 6 h; 2400 mg/day) or matching placebo from the first day of conditioning until day +14 after transplantation or neutrophil engraftment, whichever occurred first. OM was assessed daily using the World Health Organization (WHO) Oral Toxicity Scale. The primary outcomes were the incidence of any OM and severe OM (WHO grades 3-4). Safety and exploratory predictors of OM were also evaluated. RESULTS: A total of 106 patients were randomized (NAC, n = 54; placebo, n = 52) and included in the intention-to-treat efficacy analysis. Any-grade OM occurred in 33/54 patients (61.1%) receiving NAC and 38/52 patients (73.1%) receiving placebo (P = 0.190). Severe OM was significantly less frequent with NAC than with placebo (3/54 [5.6%] vs. 13/52 [25.0%]; P = 0.006), and the overall distribution of WHO grades favored NAC (P = 0.046). NAC was well tolerated; gastrointestinal adverse events were mild and infrequent. In multivariable analysis, allogeneic HCT, myeloablative conditioning, suboptimal adherence, and placebo assignment were associated with higher odds of OM. CONCLUSION: NAC mouthwash did not significantly reduce the overall incidence of OM but significantly reduced severe OM in adults undergoing HCT. Given its low cost, availability, and favorable tolerability, NAC mouthwash may be a practical supportive-care strategy for reducing clinically consequential mucosal toxicity. Multicenter trials with standardized formulations and patient-reported outcomes are warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT07325383 (registered on November 16, 2025); Iranian Registry of Clinical Trials (IRCT20140818018842N42).

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026 Oct 4 PubMed
09 Outcomes of Long-Term Absorbable Mesh Use for Ventral Hernia Repair in Immunosuppressed Patients. Joliat GR et al. 10.1002/wjs.70609
View abstract

BACKGROUND: Immunosuppressed patients are more at risk of perioperative infections. In case of ventral hernia repair, the use of a long-term absorbable mesh could potentially decrease the infectious risk in these patients. This study aimed to assess the short- and mid-term outcomes of ventral hernia repair with long-term absorbable mesh in immunosuppressed and non-immunosuppressed patients compared with permanent mesh in non-immunosuppressed patients. METHODS: A retrospective cohort study was conducted in two tertiary centers in France. Consecutive patients who underwent ventral hernia repair with a long-term absorbable (poly-4-hydroxybutyrate, P4HB) mesh between 2017 and 2024 were included. Immunosuppression was defined as a decreased immunity level caused by a disease or medication. Outcomes of these patients were compared to non-immunosuppressed patients who underwent ventral hernia repair with P4HB mesh and with synthetic mesh. RESULTS: A total of 465 patients were included: 27 in the immunosuppressed group with P4HB mesh, 232 non-immunosuppressed patients with P4HB mesh, and 206 non-immunosuppressed patients with synthetic mesh. Among patients with P4HB mesh, no differences in postoperative outcomes were found between the immunosuppressed and non-immunosuppressed groups (mean follow-up: 15 months, 95% CI 12-17). When comparing immunosuppressed patients with P4HB to non-immunosuppressed patients with synthetic mesh, the morbidity rate was higher in immunosuppressed patients (12/27 = 44% vs. 38/206 = 18%, p = 0.002), while surgical site infection, mesh infection, or recurrence rates were similar (mean follow-up: 19 months, 95% CI 16-23). Immunosuppression was not found as a predictor of surgical site infection (OR 5.0, 95% CI 0.7-10.0, p = 0.091). CONCLUSIONS: Immunosuppressed patients with P4HB mesh had similar short- and mid-term infectious complications to non-immunosuppressed patients. Long-term recurrence rates remain to be evaluated.

World journal of surgery 2026 Oct 4 PubMed
10 Dual-Targeting of ER Stress and the CD47-SIRPα Axis via an In Situ Hydrogel Prevents Postoperative Glioblastoma Recurrence. Guan X et al. 10.1002/smll.76032
View abstract

The inevitable recurrence of glioblastoma multiforme post-resection is primarily driven by infiltrative residual cells and a profoundly immunosuppressive tumor microenvironment (TME) that evades innate immune surveillance. In the present study, an injectable, photo-crosslinkable carboxymethyl chitosan (CMCS)-based hydrogel (si-HAX1&Quercetin@Gel) was engineered to achieve localized, synergistic chemo-immunotherapy within the surgical cavity. The findings demonstrate that the localized release of si-HAX1 triggers robust endoplasmic reticulum stress-mediated immunogenic cell death, leading to significant CRT surface translocation. Concurrently, Quercetin acts as a small-molecule antagonist of the CD47-signal regulatory protein α axis, dismantling the "don't eat me" shield that protects glioma cells from macrophage-mediated phagocytosis. In an in vivo postoperative glioblastoma model, the si-HAX1&Quercetin@Gel effectively suppressed tumor regrowth, increased the M1/M2 macrophage ratio and recruited CD8+ T cells, thereby extending median survival time. Moreover, this localized intervention sensitized residual tumors to intratumorally administered anti-programmed cell death protein 1 therapy by upregulating IFN-γ and remodeling the TME. By integrating biomaterial engineering with deep molecular targeting of HAX1 and CD47, we provide a robust strategy to transform the post-surgical cavity into an active immunological zone, offering a potent solution to combat malignant glioma recurrence.

Small (Weinheim an der Bergstrasse, Germany) 2026 Oct 4 PubMed
11 Dual-targeted nanotechnology for gynaecological cancers: a comprehensive review of mechanisms and clinical potential. Tu X et al. 10.1080/07853890.2026.2738261
View abstract

BACKGROUND: Ovarian, cervical and endometrial cancers have been the leading cause of morbidity and mortality in women, often resulting from late diagnosis, resistance to therapies and off-target toxicity of conventional therapies. DISCUSSION: The review discusses recent progress in the development of dual-targeted nanocarrier systems in gynaecologic oncology, relying on peer-reviewed publications in scientific databases published within the past decade. Applications of these systems are also discussed in terms of the potential to improve the selectivity and therapeutic efficiency of tumour therapy. Major available evidence is based on preclinical and models. Clinical translation is in its early-phase trials, suggesting clinical validation in gynaecologic oncology remains in its infancy. The most important challenges in translation are scalable manufacturing, long-term safety, biological complexity and regulatory challenges. CONCLUSION: This review describes the prevailing situation and constraints of dual-targeted nanotechnology, focusing on possible applications in the development of more accurate and individualized therapies for gynaecologic cancers.

Annals of medicine 2026 Dec PubMed
12 Engineering Nanoparticles to Navigate Biological Barriers for Deep Tumor Penetration. Zeng L et al. 10.1002/smll.75972
View abstract

Deep and spatially uniform drug delivery remains a major challenge in nanomedicine for solid tumor therapy. During delivery, nanoparticles must sequentially traverse multiple biological barriers, from systemic circulation and tumor accumulation to vascular extravasation, basement-membrane crossing, interstitial penetration, and cellular internalization. In this review, we distinguish the sheet-like perivascular basement membrane from the fibrillar, hydrated interstitial extracellular matrix and discuss how intertumoral, intratumoral, and stage-specific heterogeneity alters the dominant transport barriers across different tumor contexts. We then summarize three complementary strategies for engineering nanoparticles to improve deep tumor penetration: 1) Nanocarrier design, which tunes particle shape, size, surface charge, mechanical stiffness, and ligand presentation to balance cellular interactions and interstitial mobility; 2) Vascular and Stromal Modulation, which alleviates transport barriers through vascular normalization, transient basement-membrane modulation, controlled extracellular-matrix remodeling, and regulation of matrix production by cancer-associated fibroblasts; 3) Active and Assisted Transport, which promotes trans-barrier delivery through transcytosis, self-propelled nanomotors, and externally applied physical energy. We discuss the associated challenges and optimization strategies, particularly those related to spatial penetration, tumor accumulation, model-dependent efficacy, and safety. Finally, we highlight the translational limitations and future opportunities of tumor-penetrating nanomedicines from a clinical perspective.

Small (Weinheim an der Bergstrasse, Germany) 2026 Oct 4 PubMed
13 Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial. Wang Y et al. 10.1080/07853890.2026.2740294
View abstract

BACKGROUND: Evidence regarding repeated remimazolam administration remains limited. We hypothesized that remimazolam would be associated with fewer adverse events than propofol while maintaining stable sedative requirements across three repeated sedation sessions. METHODS: Patients with cervical cancer undergoing three fractions of interstitial brachytherapy were randomized to propofol or remimazolam. The primary outcome was the proportion of sedation episodes with at least one prespecified intraoperative adverse event across three sessions. Secondary outcomes included sedative dose, hemodynamics, and sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI) and Athens Insomnia Scale (AIS). RESULTS: A total of 100 participants were randomized, of whom 91 completed all three prespecified sedation sessions and were included in the primary per-protocol analysis (46 in the propofol group and 45 in the remimazolam group). Across 138 propofol and 135 remimazolam episodes, overall adverse events were less frequent with remimazolam (17.78% vs. 59.42%; RR, 0.30; 95% CI, 0.18-0.49; < 0.001). Respiratory depression (3.70% vs. 26.09%; RR, 0.14; 95% CI, 0.04-0.53; = 0.004) and hypotension (8.15% vs. 41.30%; RR, 0.20; 95% CI, 0.09-0.42; < 0.001) were also lower with remimazolam. Remimazolam requirements remained stable across sessions (third vs. first: mean difference, 0.19 mg; 95% CI, -0.78 to 1.15; = 0.846). No significant between-group differences were observed in PSQI or AIS scores. CONCLUSION: Across three consecutive sedation sessions for interstitial brachytherapy, remimazolam was associated with fewer respiratory and hemodynamic adverse events than propofol, while sedative requirements remained stable across the three sessions. TRIAL REGISTRATION: Chinese Clinical Trial Registry (identifier: ChiCTR2500108294).

Annals of medicine 2026 Dec PubMed
14 Pharmaceutical Industry Payments to Patient Groups in Australia: A Longitudinal Analysis of a Decade of Disclosures. Hooimeyer A et al. 10.5694/mja2.70294
View abstract

OBJECTIVES: To analyse the extent and patterns of pharmaceutical industry funding of patient groups in Australia between 2013 and 2022, including the proportion of groups' income derived from industry payments in 2022. STUDY TYPE: Longitudinal observational study. SETTING, PARTICIPANTS: Australia, 1 January 2013-31 December 2022. Public disclosures of payments to patient groups from pharmaceutical companies who were members of Medicines Australia (the trade organisation for the prescription pharmaceutical industry in Australia) between 2013 and 2022 and from non-member companies with at least five registered prescription products in Australia. MAIN OUTCOME MEASURES: Value (in Australian dollars) of reported payments to patient groups from the pharmaceutical industry and trends in payments by clinical area and over time. For patient groups that received industry funding in 2022, we also examined how this compared with their total income for that year. RESULTS: Between 2013 and 2022, 45 pharmaceutical companies disclosed $95.7 million in funding to 390 patient groups. Funding was highly skewed, with 13 groups receiving 47.9% ($45,856,940/$95,724,493) of the total payments. The median funding over the decade was $34,374 (interquartile range [IQR], $8228-$122,898) per group. The total reported payments decreased by $293,246 (95% confidence interval, $125,489-$461,006) per year, but some clinical areas, such as oncology, saw an increase. For groups that received funding in 2022, the median proportion of income derived from industry was 2.2% (IQR, 0.3%-9.3%) and nine groups had over half their income from industry. CONCLUSIONS: Industry funding of patient groups was widespread but skewed towards a small subset of groups and clinical areas. This may shift the focus of advocacy efforts towards certain conditions that align with current industry interests. Although further research is still needed on links between funding and patient group priorities, current disclosure measures may be insufficient to manage risks and access to other funding sources and additional safeguards may be needed to maintain independence.

The Medical journal of Australia 2026 Oct PubMed
15 Iterative Optimization of Photoactivatable BRD4 Degraders for Aging-Amplified Immunotherapy in Patient-Derived Lung Cancer Organoids. Yang J et al. 10.1002/anie.2645239
View abstract

Cancer remains a major global health threat. Targeted protein degradation (TPD) has revolutionized the modulation of protein function in therapeutic development. Nevertheless, the design of current TPD agents continues to face challenges, including hook effects and, more critically, the frequent lack of spatial and temporal precision required for in vivo applications. Herein, we report a photoactivatable targeted degradation (PATD) strategy and describe the iterative optimization of compound 9, the first two-photon-excited BRD4 photodegrader, achieved through molecular engineering of the photosensitizer core, auxiliary ligands, and linkers. Notably, BRD4 degradation downregulates GPX4 transcription, promoting lipid peroxidation and thereby inducing ferro-aging, while simultaneously triggering chemo-aging via histone H3 cleavage, which leads to DNA damage and cell cycle arrest. This dual-aging mechanism accelerates tumor cell senescence, enabling synergistic seno-immunotherapy. Beyond conventional photosensitizers that primarily elicit immunogenic cell death (ICD) alone, complex 9 integrates senescence-driven immunity with ICD-mediated antitumor immunity. This combined immunostimulatory strategy elicits robust systemic antitumor responses and achieves amplified therapeutic efficacy in patient-derived organoids (PDOs), presenting a new paradigm for precision targeted protein degradation in therapy-resistant tumors.

Angewandte Chemie (International ed. in English) 2026 Oct 4 PubMed
16 Raman Self-Tracking Copper Metal-Organic Framework-Based Nanoplatform for Cuproptosis Cancer Therapy. Duan Y et al. 10.1002/anie.9809366
View abstract

Cuproptosis represents a promising strategy for cancer therapy, yet its clinical translation is hampered by unexpected deactivation and off-target toxicity of copper ions during their delivery to tumors. We developed a copper metal-organic framework-based nanoplatform (CuF) with HO responsiveness and Raman self-tracking capability for cuproptosis-mediated antitumor therapy. CuF was prepared by coordinating Cu with an alkyne-bearing ligand, followed by PEGylation and incorporation of an iron-based catalyst. CuF undergoes catalyst-mediated oxidative cleavage of alkynyl bonds under tumor-associated elevated HO levels, causing CuF degradation and Cu release. Released Cu causes copper overload in tumor cells, thereby inducing potent cuproptosis. Meanwhile, the resultant aldehydes and acids generated by the oxidative cleavage of alkynes can further synergistically potentiate cuproptosis. Consequently, CuF demonstrated high antitumor efficacy in a 4T1 tumor-bearing mouse model (with a tumor inhibition rate of 91%). Moreover, alkynes in the metal-organic framework (MOF) backbone provided an intrinsically enhanced Raman signal, enabling label-free self-tracking of CuF distribution and degradation in cells and tissue sections through Raman imaging. Overall, this work not only provides a new paradigm for cuproptosis-based anticancer agents, but also offers a versatile strategy for engineering HO responsive materials and Raman imaging nanoplatforms.

Angewandte Chemie (International ed. in English) 2026 Oct 4 PubMed
17 Management of the neck in paranasal sinus cancers and long-term outcomes. Toprak F et al. 10.1080/00016489.2026.2740326
View abstract

BACKGROUND: Paranasal sinus malignancies are rare and frequently present at an advanced stage. The optimal management of the clinically or radiologically N0 neck remains controversial. AIMS/OBJECTIVE: To evaluate cervical lymph node management based on preoperative radiological findings and long-term oncological outcomes in patients with advanced paranasal sinus malignancies. MATERIAL AND METHODS: Thirty-four patients who underwent surgery for T3 or T4a paranasal sinus malignancies between 2014 and 2020 were retrospectively evaluated. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier analysis, and survival curves were compared using the log-rank test. RESULTS: Twenty-seven patients (79.4%) had T3 and seven (20.6%) had T4a disease. Eight patients (23.5%) had radiologically suspicious cervical lymph nodes and underwent neck dissection; two (25.0%) had pathological nodal metastasis. Cervical recurrence occurred in three patients (8.8%), and 14 (41.2%) experienced local or cervical recurrence. Five-year OS and DFS were 48.6% and 49.4%, respectively. T4a disease was associated with poorer DFS ( < 0.001). CONCLUSIONS AND SIGNIFICANCE: Cervical nodal involvement was uncommon. Our findings do not provide evidence supporting routine elective neck treatment in radiologically N0 patients. T4a disease was associated with poorer DFS.

Acta oto-laryngologica 2026 Oct 4 PubMed
18 An Oral Nanozyme Microsupplement Converts Pathological ROS Into a Colon-Adhesive Shield for Long-Term Neutrophil-Directed Remission of Ulcerative Colitis. Yu X et al. 10.1002/adma.75234
View abstract

Neutrophil extracellular traps (NETs) perpetuate chronic inflammation in ulcerative colitis (UC), yet current neutrophil-targeting therapies focus on acute intervention rather than sustained daily control. Here, we propose an oral microsupplement for long-term UC management that concurrently scavenges reactive oxygen species (ROS) and suppresses NET formation. The microsupplement integrates a catalase-mimetic CoAl-layered double hydroxide (LDH) nanozyme intercalated with the autophagy inhibitor chloroquine (CQ), together with dopamine (DOPA). The LDH nanozyme catalytically converts pathological ROS into oxygen, driving in situ polymerization of DOPA into polydopamine (PDA), a mucoadhesive polymer that prolongs colonic retention of CQ@LDH and promotes mucosal healing. RNA sequencing reveals that internalized CQ@LDH inhibits autophagic flux in neutrophils, thereby upregulating catalase expression and peroxisomal function to prevent NET formation. Consequently, NET-driven M1 macrophage polarization is reduced from 29.5% to 17.9%, and Th17 differentiation is markedly suppressed, accompanied by a decrease in colonic Th17/Treg ratio from 8.68 to 1.31. In a murine UC model, this microsupplement restores colonic mucosal integrity, rebalances the gut microbiota, and outperforms the clinical drug 5-aminosalicylic acid in both immune regulation and epithelial restitution. This neutrophil-regulating, colon-adhesive platform offers a promising strategy for routine daily UC management.

Advanced materials (Deerfield Beach, Fla.) 2026 Oct 4 PubMed
19 Engineered IFN-γ-Expressing Platelet-Like Microparticles Trigger Macrophage-Targeted Immunity to Eradicate Liver Metastases. Zhang R et al. 10.1002/adma.75242
View abstract

Immunotherapy for colorectal cancer liver metastasis is often compromised by a highly immunosuppressive hepatic microenvironment characterized by tolerogenic macrophages that act as a systemic immune sink. Here, given the potent but systemically toxic antitumor profile of interferon-γ (IFN-γ), we engineered hepatic macrophage-targeted cytokine-expressing platelet-like microparticles (HM-CPMP) for the local delivery of IFN-γ, thereby reprogramming the immune status of the liver. Mechanistically, HM-CPMP treatment drove extensive M1-like macrophage polarization and a CXCL9/10 chemotactic axis, which together shifted the liver from a tolerogenic to a pro-inflammatory state. Therefore, systemic administration of HM-CPMP facilitated the clearance of established liver metastases and conferred a marked survival benefit while strictly preserving systemic homeostasis. Intravital imaging revealed that this localized innate immune reprogramming broke the immunosuppressive tumor niche and recruited polyfunctional CXCR6 and CD8 T cells to eradicate metastatic cells. Collectively, by enabling precise hepatic immune modulation, the cytokine-expressing platelet-like microparticle delivery platform unleashes a potent localized antitumor response while preserving systemic homeostasis. Our findings provide a highly translational clinical strategy for biosynthetic cytokine-based immunotherapy against liver metastases.

Advanced materials (Deerfield Beach, Fla.) 2026 Oct 4 PubMed
20 Recent Advances in Cyclic Peptide-Based Therapeutic Strategies for Renal Cell Carcinoma: A Focused Review. Sun L et al. 10.2147/DDDT.S638461
View abstract

Renal cell carcinoma (RCC), especially clear cell RCC (ccRCC), remains difficult to control after resistance to targeted therapy or immune checkpoint blockade develops. Cyclic peptides provide conformationally constrained and chemically adaptable scaffolds for direct target modulation, tumor-selective payload delivery, radiotheranostics, supramolecular assembly, and induced-proximity pharmacology. This focused mini-review groups cyclic peptide-based strategies according to the role played by the peptide in the therapeutic system. The peptide may act as the drug itself, carry a drug or radionuclide, guide a larger carrier, assemble into a drug-delivery material, or bring two proteins together. Direct RCC evidence is anchored by carbonic anhydrase IX (CAIX)-targeted DPI-4452/ZH2 radiotheranostics, cyclic Arg-Gly-Asp (cRGD)-guided small interfering RNA (siRNA) delivery to tumor endothelium, and PB1-p62-mediated polybromo 1 (PBRM1) degradation and immune sensitization. Drug-resistant non-RCC models are retained only as transferable design evidence for efflux-evasive or self-assembling delivery. We further discuss target heterogeneity, linker and assembly stability, pharmacokinetics, renal distribution, scalable synthesis, and the experimental controls required to attribute benefit to the cyclic peptide component. Although clinical therapeutic evidence remains limited, the emerging RCC-specific studies support a mechanism-matched development strategy for this drug class.

Drug design, development and therapy 2026 PubMed
21 Updates in Hospital Medicine: Oncology. Lyu AC et al. 10.56305/001c.171947 Journal of Brown hospital medicine 2026 PubMed
22 Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs? Tieu VT et al. 10.2147/LCTT.S642874
View abstract

The development and approval of three generations of ALK tyrosine kinase inhibitors (TKIs) since the identification of anaplastic lymphoma kinase fusions () in NSCLC has led to improved survival especially with lorlatinib, the only third-generation ALK TKI in the metastatic incurable stage. The establishment of 3 years of adjuvant EGFR TKI in resected stage IB-IIIA EGFR+ NSCLC has led to improvement in overall survival (OS) when compared to placebo. Logically, the use of adjuvant ALK TKI in resected early-stage NSCLC has been investigated. But instead of three years of adjuvant TKI, in line with EGFR+ and RET+ NSCLC, the use of ALK TKI was investigated for only 2 years in both ALINA and ELEVATE trials. Unsurprisingly, alectinib (ALINA trial) and ensartinib (ELEVATE trial), respectively, has led to improved disease-free survival (DFS) so far with OS follow up on-going. Nonetheless, this is a disease that requires constant tumor suppression to prevent or delay CNS metastasis, as exemplified by the CNS data from the 7-year CROWN update. In addition, to reviewing the results of ALINA and ELEVATE, we propose two alternate novel clinical designs to build upon the 2-years of adjuvant 2G ALK TKIs.

Lung Cancer (Auckland, N.Z.) 2026 PubMed
23 Spatial Fibroblast-Macrophage Niches in Gastric Cancer: Mechanisms of Immune Exclusion, Therapeutic Resistance, and Targeted Intervention. Wang X et al. 10.2147/OTT.S645997
View abstract

Recent advances in immune checkpoint blockade, chemotherapy, anti-angiogenic therapy, and molecularly targeted therapies have expanded therapeutic options for gastric cancer. However, primary and acquired resistance remain major barriers to achieving durable clinical benefit. Tumor cell-intrinsic molecular features, including HER2 status, PD-L1 expression, MSI/MMR status, claudin 18 isoform 2 (CLDN18.2), and fibroblast growth factor receptor 2b (FGFR2b) alterations, do not fully account for the substantial heterogeneity in treatment response, highlighting the need to consider the spatial organization of the tumor microenvironment. Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are key components of this microenvironment. Evidence from single-cell sequencing, spatial transcriptomics, multiplex imaging, clinicopathological cohorts, and functional experiments indicates that CAFs and TAMs can form spatially organized niches through chemokine-mediated monocyte recruitment, macrophage-state reprogramming, extracellular matrix remodeling, complement signaling, cytokine networks, and immunometabolic regulation. Our synthesis identifies recurrent gastric cancer-associated niche archetypes, including CCL2⁺ fibroblast-STAT3-activated macrophage, GREM1⁺ fibroblast-SPP1⁺ macrophage, FAP⁺ fibroblast-SPP1⁺ macrophage, and THBS2⁺ matrix CAF-SPP1⁺ TAM niches. Among these, the THBS2⁺ matrix CAF-SPP1⁺ TAM niche in peritoneal metastasis has particularly strong spatial and functional support, including experimental evidence that CAF-derived C3 promotes C3AR1-dependent accumulation of SPP1⁺ TAMs and resistance to immune checkpoint blockade. Other proposed interactions are supported to varying degrees by spatial colocalization, ligand-receptor inference, clinicopathological association, or experimental perturbation, but their causal and clinical relevance remains incompletely established. Collectively, the available evidence suggests that selected CAF-TAM niches may promote CD8⁺ T-cell exclusion, vascular dysfunction, impaired therapeutic delivery, and persistence of treatment-resistant tumor cells. Actionable pathways include CCL2-CCR2, CSF1-CSF1R, IL-6-JAK-STAT3, CXCL12-CXCR4, SPP1-integrin, FAP, TGF-β, LOX, and C3-C3AR1. Future strategies should move beyond non-selective depletion of CAFs or macrophages and instead integrate molecular subtype, metastatic site, treatment context, and spatial biomarker patterns to identify and selectively disrupt dominant pathogenic niches.

OncoTargets and therapy 2026 PubMed
24 Choriocarcinoma at an Abdominal Wall Cesarean Scar: Recurrence After Multi-Line Chemotherapy and Exploration of Salvage Therapy. Xu S et al. 10.2147/IJWH.S640637
View abstract

Choriocarcinoma arising at an abdominal wall cesarean scar is not only exceedingly rare and diagnostically challenging but also represents a therapeutic dilemma, particularly when it becomes chemoresistant or relapses after multi-line chemotherapy. Here, we report a 40-year-old woman initially managed for suspected ectopic pregnancy with two dilation and curettage (D&C) procedures and three doses of methotrexate (MTX) therapy, but her serum β-hCG level remained persistently elevated. Further imaging examinations revealed concurrent lesions in the uterine cavity and abdominal wall cesarean scar, and subsequent surgical excision confirmed a high-risk choriocarcinoma at the scar, corresponding to a prognostic score of 10. Postoperative EMA/CO chemotherapy transiently normalized serum β-hCG levels, followed by the first recurrence. Subsequent salvage therapies (EMA/EP, re-resection, and FAV regimen) yielded only short-lived remissions, with β-hCG rebounding above 1000 mIU/mL, indicating second recurrence. Moreover, the suboptimal decline in β-hCG in response to TP/TE and FAEV regimens after the second recurrence further demonstrated the limited efficacy of chemotherapy. In addition, immunohistochemical profiling showed CD8+T cell infiltration, PD-L1 expression with a tumor proportion score of 40%, and VEGF/EGFR positivity, along with intact mismatch repair proteins. Collectively, these findings provide a rationale for the use of immune checkpoint inhibitors (ICIs), which have shown superior complete response rates in chemorefractory gestational trophoblastic neoplasia (GTN) compared with standard or high-dose chemotherapy. Notably, both the 2025 EOTTDESGOGCIGISSTD and FIGO guidelines recommend immunotherapy before high-dose chemotherapy for recurrent disease, suggesting that a personalized combination of ICIs with chemotherapy and/or anti-angiogenic agents may represent a promising salvage strategy. This case underscores the diagnostic challenge, limited durability of multi-line chemotherapy and surgery, and emerging role of immunotherapy. Early recognition, pathological confirmation, standardized chemotherapy, timely surgery, and appropriate introduction of ICIs remain key to improving outcomes in this rare entity.

International journal of women's health 2026 PubMed
25 Intracranial Mesenchymal Tumor with FET-CREB Gene Fusion: A Case Report of Late Recurrence. Xiu Y et al. 10.2147/OTT.S626927
View abstract

Intracranial mesenchymal tumors with FET‑CREB fusion represent a rare tumor entity newly defined in the 5th edition of the WHO classification of central nervous system tumors. Due to overlapping morphological features, these neoplasms were previously diagnosed under different names, including intracranial angiomatoid fibrous histiocytoma and intracranial myxoid mesenchymal tumor. Clinically, they need to be differentiated from meningioma, high‑grade glioma, solitary fibrous tumor, and other intracranial neoplasms. Most supratentorial lesions achieve good outcomes after gross total resection, and tumor recurrence is considered uncommon. We present a 58‑year‑old female patient who experienced local tumor recurrence 27 months after complete resection of a primary supratentorial cystic mass located in the right temporoparieto‑occipital region. The primary lesion was predominantly cystic with minimal solid components. Microscopically, oval and spindle‑shaped tumor cells infiltrated the cystic wall without obvious brain parenchymal invasion, accompanied by linear hemosiderin deposition. Immunohistochemically, tumor cells were diffusely positive for vimentin, MUC4, CD99, synaptophysin, EMA, and ALK (D5F3). Focal positivity was observed for CD68 and broad‑spectrum cytokeratin. All other markers including SMA, MyoD1, HMB45, myogenin, TFE3, MelanA, SOX10, SSTR2, PR, GFAP, and Oligo2 were negative. INI1 expression was intact in all tumor nuclei. The Ki‑67 proliferation index increased from 5%-10% in the primary lesion to 10%-15% in the recurrent specimen. Both primary and recurrent tumors harbored identical EWSR1::ATF1 fusion confirmed by next‑generation sequencing and FISH analysis. The patient received no adjuvant therapy after the first operation, and delayed recurrence was detected during routine MRI follow‑up. A combination of radiological findings, histopathology, immunohistochemistry, and molecular testing is essential for accurate diagnosis of this rare tumor. This case describes late tumor recurrence in an adult patient with typical low‑risk features, including supratentorial location and complete surgical resection. Our findings expand the clinical and pathological spectrum of EWSR1::ATF1‑fused intracranial mesenchymal tumors. Long‑term imaging surveillance is necessary even for patients with favorable clinical factors. Standardized follow‑up protocols and optimal adjuvant treatment strategies remain undefined and require further validation in larger cohorts.

OncoTargets and therapy 2026 PubMed
26 Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy Moushumi Suryavanshi et al. 10.1186/s12885-026-15894-7 BMC Cancer 2026 Scholar
27 Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS). A. Kapoor et al. 10.1200/GO-25-00721 JCO global oncology 2026 Scholar
28 Resection margin width as a risk factor for liver cancer recurrence M. Kamalova et al. 10.17816/onco703999 Russian Journal of Oncology 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Cancer & Oncology
  • Week: September 28 – October 5, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 7:29 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —